Novo Nordisk strikes deal with startup to develop oral obesity, diabetes drugs
Novo Nordisk strikes deal with startup to develop oral obesity, diabetes drugs is drawing significant interest across the industry.
Vivtex, a biotech startup based in Boston, was co-founded by renowned MIT professor Robert Langer and others.
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Not funding, not management: Founder finds house hunting to be the biggest challenge. Landlords want to enter the flat whenever they want
- Bill Gates' Key Climate Tech Fund Halts New Investment, Lays Off Workers
- valuable company to fulfill a funding promise to Sam Altman; Japanese giant Softbank says: Nothing ...
- India Inc won’t fund R&D-but it might bankroll an escape from reality
Source: Original →